Proteomic comparison of oligodendrogliomas with and without 1pLOH

Hiroaki Okamoto, Jie Li, Sven Gläsker, Alexander Vortmeyer, Howard Jaffe, R. Aaron Robison, Oliver Bogler, Tom Mikkelsen, Irina A. Lubensky, Edward H. Oldfield, Zhengping Zhuang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: Chemoresistance is a widespread therapeutic challenge in glial tumors. The molecular basis of chemoresistance is poorly understood, precluding advances in glioma treatment and leaving gliomas among the most lethal tumors. Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity. Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH. Methods: In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling. Proteomic analysis was performed by two-dimensional protein gel electrophoresis and subsequent computerized gel analysis for detection of distinguishing patterns of protein expression. Differentially expressed proteins were identified using Liquid Chromatography/Mass Spectrometry. Differential expression of select proteins was confirmed by Western blotting. Results: We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH. Two of these proteins (glyoxalase I and Rho GDP dissociation inhibitor) have previously been shown to enhance chemoresistance in other tumors. In turn, we identified twelve overexpressed proteins in tumors with 1pLOH that have previously been reported to induce chemosensitivity in other forms of human neoplasia. Conclusions: These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.

Original languageEnglish (US)
Pages (from-to)391-396
Number of pages6
JournalCancer Biology and Therapy
Volume6
Issue number3
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Oligodendroglioma
Proteomics
Proteins
Glioma
Neoplasms
Guanine Nucleotide Dissociation Inhibitors
Lactoylglutathione Lyase
Loss of Heterozygosity
Chromosomes, Human, Pair 1
Electrophoresis, Gel, Two-Dimensional
Proteome
Neuroglia
Liquid Chromatography
Mass Spectrometry
Biomarkers
Western Blotting
Gels
Pharmacology

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Okamoto, H., Li, J., Gläsker, S., Vortmeyer, A., Jaffe, H., Robison, R. A., ... Zhuang, Z. (2007). Proteomic comparison of oligodendrogliomas with and without 1pLOH. Cancer Biology and Therapy, 6(3), 391-396. https://doi.org/10.4161/cbt.6.3.3731

Proteomic comparison of oligodendrogliomas with and without 1pLOH. / Okamoto, Hiroaki; Li, Jie; Gläsker, Sven; Vortmeyer, Alexander; Jaffe, Howard; Robison, R. Aaron; Bogler, Oliver; Mikkelsen, Tom; Lubensky, Irina A.; Oldfield, Edward H.; Zhuang, Zhengping.

In: Cancer Biology and Therapy, Vol. 6, No. 3, 01.01.2007, p. 391-396.

Research output: Contribution to journalArticle

Okamoto, H, Li, J, Gläsker, S, Vortmeyer, A, Jaffe, H, Robison, RA, Bogler, O, Mikkelsen, T, Lubensky, IA, Oldfield, EH & Zhuang, Z 2007, 'Proteomic comparison of oligodendrogliomas with and without 1pLOH', Cancer Biology and Therapy, vol. 6, no. 3, pp. 391-396. https://doi.org/10.4161/cbt.6.3.3731
Okamoto, Hiroaki ; Li, Jie ; Gläsker, Sven ; Vortmeyer, Alexander ; Jaffe, Howard ; Robison, R. Aaron ; Bogler, Oliver ; Mikkelsen, Tom ; Lubensky, Irina A. ; Oldfield, Edward H. ; Zhuang, Zhengping. / Proteomic comparison of oligodendrogliomas with and without 1pLOH. In: Cancer Biology and Therapy. 2007 ; Vol. 6, No. 3. pp. 391-396.
@article{f27c21b160c449239caa3cd3194f688f,
title = "Proteomic comparison of oligodendrogliomas with and without 1pLOH",
abstract = "Objective: Chemoresistance is a widespread therapeutic challenge in glial tumors. The molecular basis of chemoresistance is poorly understood, precluding advances in glioma treatment and leaving gliomas among the most lethal tumors. Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity. Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH. Methods: In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling. Proteomic analysis was performed by two-dimensional protein gel electrophoresis and subsequent computerized gel analysis for detection of distinguishing patterns of protein expression. Differentially expressed proteins were identified using Liquid Chromatography/Mass Spectrometry. Differential expression of select proteins was confirmed by Western blotting. Results: We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH. Two of these proteins (glyoxalase I and Rho GDP dissociation inhibitor) have previously been shown to enhance chemoresistance in other tumors. In turn, we identified twelve overexpressed proteins in tumors with 1pLOH that have previously been reported to induce chemosensitivity in other forms of human neoplasia. Conclusions: These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.",
author = "Hiroaki Okamoto and Jie Li and Sven Gl{\"a}sker and Alexander Vortmeyer and Howard Jaffe and Robison, {R. Aaron} and Oliver Bogler and Tom Mikkelsen and Lubensky, {Irina A.} and Oldfield, {Edward H.} and Zhengping Zhuang",
year = "2007",
month = "1",
day = "1",
doi = "10.4161/cbt.6.3.3731",
language = "English (US)",
volume = "6",
pages = "391--396",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Proteomic comparison of oligodendrogliomas with and without 1pLOH

AU - Okamoto, Hiroaki

AU - Li, Jie

AU - Gläsker, Sven

AU - Vortmeyer, Alexander

AU - Jaffe, Howard

AU - Robison, R. Aaron

AU - Bogler, Oliver

AU - Mikkelsen, Tom

AU - Lubensky, Irina A.

AU - Oldfield, Edward H.

AU - Zhuang, Zhengping

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Objective: Chemoresistance is a widespread therapeutic challenge in glial tumors. The molecular basis of chemoresistance is poorly understood, precluding advances in glioma treatment and leaving gliomas among the most lethal tumors. Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity. Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH. Methods: In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling. Proteomic analysis was performed by two-dimensional protein gel electrophoresis and subsequent computerized gel analysis for detection of distinguishing patterns of protein expression. Differentially expressed proteins were identified using Liquid Chromatography/Mass Spectrometry. Differential expression of select proteins was confirmed by Western blotting. Results: We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH. Two of these proteins (glyoxalase I and Rho GDP dissociation inhibitor) have previously been shown to enhance chemoresistance in other tumors. In turn, we identified twelve overexpressed proteins in tumors with 1pLOH that have previously been reported to induce chemosensitivity in other forms of human neoplasia. Conclusions: These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.

AB - Objective: Chemoresistance is a widespread therapeutic challenge in glial tumors. The molecular basis of chemoresistance is poorly understood, precluding advances in glioma treatment and leaving gliomas among the most lethal tumors. Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity. Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH. Methods: In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling. Proteomic analysis was performed by two-dimensional protein gel electrophoresis and subsequent computerized gel analysis for detection of distinguishing patterns of protein expression. Differentially expressed proteins were identified using Liquid Chromatography/Mass Spectrometry. Differential expression of select proteins was confirmed by Western blotting. Results: We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH. Two of these proteins (glyoxalase I and Rho GDP dissociation inhibitor) have previously been shown to enhance chemoresistance in other tumors. In turn, we identified twelve overexpressed proteins in tumors with 1pLOH that have previously been reported to induce chemosensitivity in other forms of human neoplasia. Conclusions: These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.

UR - http://www.scopus.com/inward/record.url?scp=34548218234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548218234&partnerID=8YFLogxK

U2 - 10.4161/cbt.6.3.3731

DO - 10.4161/cbt.6.3.3731

M3 - Article

C2 - 17264672

AN - SCOPUS:34548218234

VL - 6

SP - 391

EP - 396

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -